- Stocks
- Healthcare
- NASDAQ: HZNP

Price (delayed)

$109.96

Market cap

$24.84B

P/E Ratio

45.07

Dividend/share

N/A

EPS

$2.44

Enterprise value

$26.6B

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company pipeline is purposeful: it applyie scientific expertise

HZNP's net income has surged by 85% since the previous quarter

HZNP's gross profit has soared by 74% year-on-year and by 18% since the previous quarter

Horizon Therapeutics's EPS has soared by 85% from the previous quarter but it has decreased by 14% YoY

The company's debt has surged by 119% YoY

The stock's price to earnings (P/E) is 10% more than its last 4 quarters average of 41.3

Sector: Healthcare

Industry: Drug Manufacturers - General

Website: http://www.horizontherapeutics.com

What are the main financial stats of HZNP

Market
Valuations
Earnings

Shares outstanding

225.89M

Market cap

$24.84B

Enterprise value

$26.6B

Price to earnings (P/E)

45.07

Price to book (P/B)

6.07

Price to sales (P/S)

9.68

EV/EBIT

61.07

EV/EBITDA

36.02

EV/Sales

10.4

Revenue

$2.56B

EBIT

$435.58M

EBITDA

$738.37M

Free cash flow

$527.62M

Per share
Balance sheet
Liquidity

EPS

$2.44

Free cash flow per share

$2.34

Book value per share

$18.12

Revenue per share

$11.36

TBVPS

$17.85

Total assets

$8.21B

Total liabilities

$4.13B

Debt

$2.58B

Equity

$4.07B

Working capital

$1.32B

Debt to equity

0.63

Current ratio

2.55

Quick ratio

1.82

Net debt/EBITDA

2.38

Margins
Efficiency
Dividend

EBITDA margin

28.9%

Gross margin

75.9%

Net margin

20.3%

Operating margin

17.6%

Return on assets

7.4%

Return on equity

13.2%

Return on invested capital

13%

Return on capital employed

5.9%

Return on sales

17%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Horizon Therapeutics stock price performed over time

Intraday

-0.37%

1 week

1.8%

1 month

1.6%

1 year

40.52%

YTD

50.32%

QTD

17.43%

How have Horizon Therapeutics's revenue and profit performed over time

Revenue

$2.56B

Gross profit

$1.94B

Operating income

$450.43M

Net income

$518.16M

Gross margin

75.9%

Net margin

20.3%

The company's operating margin has surged by 112% YoY and by 9% QoQ

HZNP's net income has surged by 85% since the previous quarter

HZNP's gross profit has soared by 74% year-on-year and by 18% since the previous quarter

Horizon Therapeutics's revenue has soared by 68% YoY and by 17% from the previous quarter

What is Horizon Therapeutics's growth rate over time

What is Horizon Therapeutics stock price valuation

P/E

45.07

P/B

6.07

P/S

9.68

EV/EBIT

61.07

EV/EBITDA

36.02

EV/Sales

10.4

Horizon Therapeutics's EPS has soared by 85% from the previous quarter but it has decreased by 14% YoY

The stock's price to earnings (P/E) is 10% more than its last 4 quarters average of 41.3

HZNP's price to book (P/B) is 96% higher than its 5-year quarterly average of 3.1 and 30% higher than its last 4 quarters average of 4.7

The equity has soared by 72% year-on-year and by 6% since the previous quarter

HZNP's price to sales (P/S) is 126% more than its 5-year quarterly average of 4.3 and 16% more than its last 4 quarters average of 8.4

Horizon Therapeutics's revenue has soared by 68% YoY and by 17% from the previous quarter

How efficient is Horizon Therapeutics business performance

HZNP's ROE has soared by 65% from the previous quarter but it is down by 47% YoY

Horizon Therapeutics's return on assets has surged by 61% QoQ but it has decreased by 39% YoY

Horizon Therapeutics's ROS has increased by 16% from the previous quarter

HZNP's return on invested capital is up by 4% since the previous quarter

What is HZNP's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for HZNP.

How did Horizon Therapeutics financials performed over time

The total assets is 99% more than the total liabilities

The company's total liabilities has surged by 90% YoY and by 3.6% QoQ

The total assets has soared by 81% YoY and by 4.6% from the previous quarter

The company's debt is 37% lower than its equity

The company's debt has surged by 119% YoY

The equity has soared by 72% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.